Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGJ398 in Tumor-Induced Osteomalacia
NCT03510455Phase 2Terminated
- Sponsor
- National Institute of Dental and Craniofacial Research
- Start
- Feb 2019
- Primary completion
- Feb 2020
- Countries
- 1
01
Overview
A Phase 2 trial of infigratinib in tumor-induced osteomalacia (TIO), sponsored by National Institute of Dental and Craniofacial Research. Started Feb 2019; status: terminated.
02
Drugs
infigratinib
03
Conditions
tumor-induced osteomalacia (TIO)
Beyond the preview
Go deeper on NCT03510455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03510455.